Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

NCT00079313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Chronic Myelogenous Leukemia

Interventions

DRUG: Imatinib

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)